MEDICAL TECHNOLOGY ENTERPRISE CONSORTIUM
Capabilities
We advance cutting-edge medical technologies that improve the health of the military and civilians across the globe.
Digital Health Technologies
Reconstruction, rehabilitation, and definitive care for injured personnel to improve the standard of care and outcomes, return service members to full form and function, and ultimately restore personnel to duty and improve his or her quality of life.
Diagnostics
Maximize health, readiness, and performance by countering stressors and preventing physical and psychological injuries during training and operations.
Routes of Administration
Transition more capable healthcare information and medical simulation technologies into military healthcare relevant applications.
Medical Devices
Prevent, predict, and treat infectious disease threats to eliminate their impacts on operational readiness and performance.
Application Area
Transition more capable healthcare information and medical simulation technologies into military healthcare relevant applications
Additional Capabilities
Medical Technology Enterprise Consortium (MTEC)
The Power of IP: Why It Matters to MTEC and Our Mission
MTEC President highlights intellectual property as essential to protecting innovation, attracting investment, and enabling collaboration. A new partnership with Patenter.io supports members in managing and commercializing IP.
BrightFocus Foundation
Unlikely Alliances: Building Funding Partnerships That Bridge Interests
A case study of civilian and military partnerships illustrates how finding an intersection of very different perspectives and very different funding approaches together to advance mutual interests.
George Mason University
SMART-US Wearable Ultrasound + AI Device for Muscle Force Prediction
AI-powered ultrasound in a wearable—SMART-US delivers lab-grade muscle-force insights anywhere.
BiomX
BiomX Achieves Positive Phase 2 Results for BX211 in Treating Diabetic Foot Osteomyelitis
BiomX has reported positive Phase 2 results for BX211, its personalized phage therapy for Diabetic Foot Osteomyelitis (DFO). The treatment significantly improved ulcer healing, showing promise for reducing amputation risk. Supported by NMRC and MTEC, BX211 may offer new hope for both military and civilian patients.
We are here to help
Are you a federal agency in need of innovative solutions?
Let’s Get Started